Aclaris Therapeutics Stock Today
| ACRS Stock | USD 4.32 0.36 9.09% |
Performance18 of 100
| Odds Of DistressLess than 30
|
Aclaris Therapeutics is selling for under 4.32 as of the 22nd of November 2024; that is 9.09 percent increase since the beginning of the trading day. The stock's lowest day price was 3.96. Aclaris Therapeutics has about a 30 percent probability of financial distress in the next few years of operation but had a somewhat solid performance during the last 90 days. Equity ratings for Aclaris Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of October 2015 | Category Healthcare | Classification Health Care |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 71.43 M outstanding shares of which 2.41 M shares are presently shorted by private and institutional investors with about 3.56 trading days to cover. More on Aclaris Therapeutics
Moving against Aclaris Stock
Aclaris Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President, CoFounder | Neal DO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAclaris Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aclaris Therapeutics' financial leverage. It provides some insight into what part of Aclaris Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aclaris Therapeutics (ACRS) is traded on NASDAQ Exchange in USA. It is located in 701 Lee Road, Wayne, PA, United States, 19087 and employs 86 people. Aclaris Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 282.87 M. Aclaris Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 71.43 M outstanding shares of which 2.41 M shares are presently shorted by private and institutional investors with about 3.56 trading days to cover.
Aclaris Therapeutics currently holds about 248.6 M in cash with (78.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73.
Check Aclaris Therapeutics Probability Of Bankruptcy
Ownership AllocationAclaris Therapeutics holds a total of 71.43 Million outstanding shares. The majority of Aclaris Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aclaris Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aclaris Therapeutics. Please pay attention to any change in the institutional holdings of Aclaris Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aclaris Ownership Details
Aclaris Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Aldebaran Capital Llc | 2024-09-30 | 1 M | |
| Bain Capital Life Sciences Investors, Llc | 2024-06-30 | 1000 K | |
| Qube Research & Technologies | 2024-06-30 | 940.8 K | |
| Deutsche Bank Ag | 2024-06-30 | 923.3 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 916.6 K | |
| Citadel Advisors Llc | 2024-06-30 | 875.2 K | |
| Geode Capital Management, Llc | 2024-06-30 | 774.1 K | |
| Samsara Biocapital, Llc | 2024-09-30 | 696.2 K | |
| Palo Alto Investors, Llc | 2024-06-30 | 569.8 K | |
| Bml Capital Management Llc | 2024-09-30 | 14.2 M | |
| Vanguard Group Inc | 2024-09-30 | 4.7 M |
Aclaris Therapeutics Historical Income Statement
Aclaris Stock Against Markets
Aclaris Therapeutics Corporate Management
| Joseph Monahan | Chief Officer | Profile | |
| Gail MD | Chief Officer | Profile | |
| Robert Doody | VP Relations | Profile | |
| Matthew JD | General Secretary | Profile |
Already Invested in Aclaris Therapeutics?
The danger of trading Aclaris Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aclaris Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aclaris Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aclaris Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.